Elimination of GD3 synthase improves memory and reduces amyloid-β plaque load in transgenic mice

Neurobiology of Aging

Volumn 30, Issue 11, 2009, Pages 1777-1791

  Bernardo, Alexandra ^a,b   Harrison, Fiona E ^a,b   McCord, Meghan ^b   Zhao, Jiali ^a   Bruchey, Aleksandra ^b   Davies, Sean S ^a   Jackson Roberts II, L ^a   Mathews, Paul M ^c   Matsuoka, Yasuji ^d   Ariga, Toshio ^e   Yu, Robert K ^e   Thompson, Rebecca ^b   McDonald, Michael P ^a,b,f  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

A ; Alzheimer's disease; Amyloid precursor protein; Apoptosis; Behavior; Gangliosides; GD1a; GD1b GT1b; GD3; GD3 synthase; GM1; Lipid rafts; Memory; Neuroinflammation; Oxidative stress; Plaque

Indexed keywords

AMYLOID BETA PROTEIN; GANGLIOSIDE; GANGLIOSIDE GD3 SYNTHASE; SYNTHETASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HISTOLOGY; LEARNING; MALE; MEMORY; MOUSE; MUTANT; NERVE DEGENERATION; NERVOUS TISSUE; NEUROCHEMISTRY; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN INTERACTION; RAT; TASK PERFORMANCE; TRANSGENIC MOUSE; TRANSGENICS; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIGENS, CD11B; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIPID PEROXIDATION; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MUTATION; NEURONS; PLAQUE, AMYLOID; PRESENILIN-1; PROTEIN BINDING; SIALYLTRANSFERASES;

EID: 67649453609     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.12.022     Document Type: Article

References (94)

1. Ariga T., and Yu R.K. GM1 inhibits amyloid beta-protein-induced cytokine release. Neurochem. Res 24 (1999) 219-226
2. Ariga T., Kobayashi K., Kuroda Y., Yu R.K., Suzuki M., Kitagawa H., Inagaki F., and Miyatake T. Characterization of tumor-associated fucogangliosides from PC 12 pheochromocytoma cells. J. Biol. Chem. 262 (1987) 14146-14153
3. Ariga T., Kobayashi K., Hasegawa A., Kiso M., Ishida H., and Miyatake T. Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch. Biochem. Biophys. 388 (2001) 225-230
4. Augustinsson L.E., Blennow K., Blomstrand C., Brane G., Ekman R., Fredman P., Karlsson I., Kihlgren M., Lehmann W., Lekman A., Mansson J.E., Ramstrom I., Wallin A., Wikkelso C., Gottfries C.G., and Svennerholm L. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dement. Geriatr. Cogn. Disord. 8 (1997) 26-33
5. Bachis A., Rabin S.J., Del Fiacco M., and Mocchetti I. Gangliosides prevent excitotoxicity through activation of TrkB receptor. Neurotox. Res. 4 (2002) 225-234
6. Bambrick L.L., de Grip A., Seenivasan V., Krueger B.K., and Yarowsky P.J. Expression of glial antigens in mouse astrocytes: species differences and regulation in vitro. J. Neurosci. Res. 46 (1996) 305-315
7. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 93 (1979) 74-104
8. Barnes C.A. Spatial learning and memory processes: the search for their neurobiological mechanisms in the rat. Trends Neurosci. 11 (1988) 163-169
9. Bernardo A., McCord M., Troen A.M., Allison J.D., and McDonald M.P. Impaired spatial memory in APP-overexpressing mice on a homocysteinemia-inducing diet. Neurobiol. Ageing 28 (2007) 1195-1205
10. Bornemann K.D., Wiederhold K.H., Pauli C., Ermini F., Stalder M., Schnell L., Sommer B., Jucker M., and Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. 158 (2001) 63-73
11. Casamenti F., Bracco L., Bartolini L., and Pepeu G. Effects of ganglioside treatment in rats with a lesion of the cholinergic forebrain nuclei. Brain Res. 338 (1985) 45-52
12. Choo-Smith L.P., and Surewicz W.K. The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett. 402 (1997) 95-98
13. Choo-Smith L.P., Garzon-Rodriguez W., Glabe C.G., and Surewicz W.K. Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272 (1997) 22987-22990
14. Copani A., Melchiorri D., Caricasole A., Martini F., Sale P., Carnevale R., Gradini R., Sortino M.A., Lenti L., De Maria R., and Nicoletti F. Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. J. Neurosci. 22 (2002) 3963-3968
15. De Maria R., Lenti L., Malisan F., d'Agostino F., Tomassini B., Zeuner A., Rippo M.R., and Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science 277 (1997) 1652-1655
16. Drago J., Reid K.L., and Bartlett P.F. Induction of the ganglioside marker A2B5 on cultured cerebellar neural cells by growth factors. Neurosci. Lett. 107 (1989) 245-250
17. Eckert A., Keil U., Marques C.A., Bonert A., Frey C., Schussel K., and Muller W.E. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem. Pharmacol. 66 (2003) 1627-1634
18. Emerich D.F., and Walsh T.J. Selective working memory impairments following intradentate injection of colchicine: attenuation of the behavioral but not the neuropathological effects by gangliosides GM1 and AGF2. Physiol. Behav. 45 (1989) 93-101
19. Ferrari G., and Greene L.A. Prevention of neuronal apoptotic death by neurotrophic agents and ganglioside GM1: insights and speculations regarding a common mechanism. Perspect. Dev. Neurobiol. 3 (1996) 93-100
20. Fighera M.R., Royes L.F., Furian A.F., Oliveira M.S., Fiorenza N.G., Frussa-Filho R., Petry J.C., Coelho R.C., and Mello C.F. GM1 ganglioside prevents seizures, Na+, K+-ATPase activity inhibition and oxidative stress induced by glutaric acid and pentylenetetrazole. Neurobiol. Dis. 22 (2006) 611-623
21. Flicker C., Ferris S.H., Kalkstein D., and Serby M. A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease. Am. J. Psychiatry 151 (1994) 126-129
22. Fong T.G., Neff N.H., and Hadjiconstantinou M. GM1 ganglioside improves spatial learning and memory of aged rats. Behav. Brain Res. 85 (1997) 203-211
23. Garcia-Ruiz C., Colell A., Paris R., and Fernandez-Checa J.C. Direct interaction of GD3 ganglioside with mitochondria generates reactive oxygen species followed by mitochondrial permeability transition, cytochrome c release, and caspase activation. FASEB J. 14 (2000) 847-858
24. Gellermann G.P., Appel T.R., Tannert A., Radestock A., Hortschansky P., Schroeckh V., Leisner C., Lutkepohl T., Shtrasburg S., Rocken C., Pras M., Linke R.P., Diekmann S., and Fandrich M. Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 6297-6302
25. Glasier M.M., Sutton R.L., and Stein D.G. Effects of unilateral entorhinal cortex lesion and ganglioside GM1 treatment on performance in a novel water maze task. Neurobiol. Learn Mem. 64 (1995) 203-214
26. Glasier M.M., Janis L.S., Goncalves M.I., and Stein D.G. GM1 produces attenuation of short-term memory deficits in Hebb-Williams maze performance after unilateral entorhinal cortex lesions. Physiol. Behav. 66 (1999) 441-446
27. Haass C., Koo E.H., Mellon A., Hung A.Y., and Selkoe D.J. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357 (1992) 500-503
28. Harrison F.E., Reiserer R.S., Tomarken A.J., and McDonald M.P. Spatial and nonspatial escape strategies in the Barnes maze. Learn Mem. 13 (2006) 809-819
29. Hayashi H., Kimura N., Yamaguchi H., Hasegawa K., Yokoseki T., Shibata M., Yamamoto N., Michikawa M., Yoshikawa Y., Terao K., Matsuzaki K., Lemere C.A., Selkoe D.J., Naiki H., and Yanagisawa K. A seed for Alzheimer amyloid in the brain. J. Neurosci. 24 (2004) 4894-4902
30. Hicks D., Heidinger V., Mohand-Said S., Sahel J., and Dreyfus H. Growth factors and gangliosides as neuroprotective agents in excitotoxicity and ischemia. Gen. Pharmacol. 30 (1998) 265-273
31. Hof P.R., Young W.G., Bloom F.E., Belichenko P.V., and Celio M.R. Comparative Cytoarchitectonic Atlas of the C57BL6 and 129Sv Mouse Brains (2000), Elsevier, New York
32. Holmes A., Wrenn C.C., Harris A.P., Thayer K.E., and Crawley J.N. Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav. 1 (2002) 55-69
33. Horikoshi Y., Sakaguchi G., Becker A.G., Gray A.J., Duff K., Aisen P.S., Yamaguchi H., Maeda M., Kinoshita N., and Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem. Biophys. Res. Commun. 319 (2004) 733-737
34. Huettner J.E., and Baughman R.W. Primary culture of identified neurons from the visual cortex of postnatal rats. J. Neurosci. 6 (1986) 3044-3060
35. Itagaki S., McGeer P.L., Akiyama H., Zhu S., and Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24 (1989) 173-182
36. Kakio A., Nishimoto S.I., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276 (2001) 24985-24990
37. Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41 (2002) 7385-7390
38. Kalanj S., Kracun I., Rosner H., and Cosovic C. Regional distribution of brain gangliosides in Alzheimer's disease. Neurol. Croat. 40 (1991) 269-281
39. Kawai H., Allende M.L., Wada R., Kono M., Sango K., Deng C., Miyakawa T., Crawley J.N., Werth N., Bierfreund U., Sandhoff K., and Proia R.L. Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. J. Biol. Chem. 276 (2001) 6885-6888
40. Kim S.I., Yi J.S., and Ko Y.G. Amyloid beta oligomerization is induced by brain lipid rafts. J. Cell Biochem. 99 (2006) 878-889
41. Knapp P.E. Studies of glial lineage and proliferation in vitro using an early marker for committed oligodendrocytes. J. Neurosci. Res. 30 (1991) 336-345
42. Kracun I., Kalanj S., Talan-Hranilovic J., and Cosovic C. Cortical distribution of gangliosides in Alzheimer's disease. Neurochem. Int. 20 (1992) 433-438
43. Kristal B.S., and Brown A.M. Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition. J. Biol. Chem. 274 (1999) 23169-23175
44. Kurganov B., Doh M., and Arispe N. Aggregation of liposomes induced by the toxic peptides Alzheimer's Abetas, human amylin and prion (106-126): facilitation by membrane-bound GM1 ganglioside. Peptides 25 (2004) 217-232
45. Lalonde R., Kim H.D., and Fukuchi K. Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice. Neurosci. Lett. 369 (2004) 156-161
46. Lalonde R., Kim H.D., Maxwell J.A., and Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co + PS1/DeltaE9 mice with amyloid plaques. Neurosci. Lett. 390 (2005) 87-92
47. Liao M.Q., Tzeng Y.J., Chang L.Y., Huang H.B., Lin T.H., Chyan C.L., and Chen Y.C. The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. FEBS Lett. 581 (2007) 1161-1165
48. Liu Y., Hoffmann A., Grinberg A., Westphal H., McDonald M.P., Miller K.M., Crawley J.N., Sandhoff K., Suzuki K., and Proia R.L. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 8138-8143
49. Lombardi G., Zanoni R., and Moroni F. Systemic treatments with GM1 ganglioside reduce quinolinic acid-induced striatal lesions in the rat. Eur. J. Pharmacol. 174 (1989) 123-125
50. Magoski N.S., Walz W., and Juurlink B.H. Identification of mouse type-2-like astrocytes: demonstration of glutamate and GABA transmitter activated responses. J. Neurosci. Res. 33 (1992) 91-102
51. Mahadik S.P., Vilim F., Korenovsky A., and Karpiak S.E. GM1 ganglioside protects nucleus basalis from excitotoxin damage: reduced cortical cholinergic losses and animal mortality. J. Neurosci. Res. 20 (1988) 479-483
52. Mahadik S.P., Hungund B.L., Gokhale V.S., Ortiz A., Makar T.K., and Karpiak S.E. Monosialoganglioside (GM1) restores membrane fatty acid levels in ischemic tissue after cortical focal ischemia in rat. Neurochem. Int. 23 (1993) 163-172
53. Malisan F., and Testi R. The ganglioside GD3 as the Greek goddess Hecate: several faces turned towards as many directions. IUBMB Life 57 (2005) 477-482
54. Masliah E., Hansen L., Albright T., Mallory M., and Terry R.D. Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease. Acta Neuropathol. (Berl.) 81 (1991) 428-433
55. Matsuoka Y., Saito M., LaFrancois J., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., and Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23 (2003) 29-33
56. Matsuzaki K., and Horikiri C. Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry 38 (1999) 4137-4142
57. McDonald M.P., and Overmier J.B. Present imperfect: a critical review of animal models of the mnemonic impairments in Alzheimer's disease. Neurosci. Biobehav. Rev. 22 (1998) 99-120
58. McDonald M.P., Dahl E.E., Overmier J.B., Mantyh P., and Cleary J. Effects of an exogenous beta-amyloid peptide on retention for spatial learning. Behav. Neural. Biol. 62 (1994) 60-67
59. McDonald M.P., Overmier J.B., Bandyopadhyay S., Babcock D., and Cleary J. Reversal of beta-amyloid-induced retention deficit after exposure to training and state cues. Neurobiol. Learn Mem. 65 (1996) 35-47
60. McDonald M.P., Wenk G.L., and Crawley J.N. Analysis of galanin and the galanin antagonist M40 on delayed non-matching-to-position performance in rats lesioned with the cholinergic immunotoxin 192 IgG-saporin. Behav. Neurosci. 111 (1997) 552-563
61. McDonald M.P., Willard L.B., Wenk G.L., and Crawley J.N. Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions. J. Neurosci. 18 (1998) 5078-5085
62. McLaurin J., and Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 271 (1996) 26482-26489
63. McLaurin J., Franklin T., Fraser P.E., and Chakrabartty A. Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J. Biol. Chem. 273 (1998) 4506-4515
64. Meda L., Cassatella M.A., Szendrei G.I., Otvos Jr. L., Baron P., Villalba M., Ferrari D., and Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374 (1995) 647-650
65. Melnikova T., Savonenko A., Wang Q., Liang X., Hand T., Wu L., Kaufmann W.E., Vehmas A., and Andreasson K.I. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 141 (2006) 1149-1162
66. Miyakawa T., Yamada M., Duttaroy A., and Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci. 21 (2001) 5239-5250
67. Miyakawa T., Yared E., Pak J.H., Huang F.L., Huang K.P., and Crawley J.N. Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus 11 (2001) 763-775
68. Nishitomi K., Sakaguchi G., Horikoshi Y., Gray A.J., Maeda M., Hirata-Fukae C., Becker A.G., Hosono M., Sakaguchi I., Minami S.S., Nakajima Y., Li H.F., Takeyama C., Kihara T., Ota A., Wong P.C., Aisen P.S., Kato A., Kinoshita N., and Matsuoka Y. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J. Neurochem. 99 (2006) 1555-1563
69. Nobile-Orazio E., Carpo M., Meucci N., Grassi M.P., Capitani E., Sciacco M., Mangoni A., and Scarlato G. Guillain-Barre syndrome associated with high titers of anti-GM1 antibodies. J. Neurol. Sci. 109 (1992) 200-206
70. Odaka M., Yuki N., Nobile-Orazio E., Carpo M., and Hirata K. Antibodies to GM1(NeuGc) in Guillain-Barre syndrome after ganglioside therapy. J. Neurol. Sci. 175 (2000) 96-106
71. Pompl P.N., Mullan M.J., Bjugstad K., and Arendash G.W. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. J. Neurosci. Methods 87 (1999) 87-95
72. Rahmann H. Brain gangliosides and memory formation. Behav. Brain Res. 66 (1995) 105-116
73. Reiserer R.S., Harrison F.E., Syverud D.C., and McDonald M.P. Impaired spatial learning in the APP + PSEN1 DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 6 (2007) 54-65
74. Roberts II L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., Dettbarn W.D., and Morrow J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273 (1998) 13605-13612
75. Roeser C., Cassel J.C., and Kelche C. Behavioral effects of GM1 ganglioside treatment and intrahippocampal septal grafts in rats with fimbria-fornix lesions. Exp. Brain Res. 115 (1997) 520-530
76. Sango K., McDonald M.P., Crawley J.N., Mack M.L., Tifft C.J., Skop E., Starr C.M., Hoffmann A., Sandhoff K., Suzuki K., and Proia R.L. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat. Genet. 14 (1996) 348-352
77. Santucci A.C., Gluck R., Kanof P.D., and Haroutunian V. Induction of memory and cortical cholinergic neurochemical recovery with combine fetal transplantation and GM1 treatments in rats with lesions of the NBM. Dementia 4 (1993) 273-281
78. Sasaki A., Shoji M., Harigaya Y., Kawarabayashi T., Ikeda M., Naito M., Matsubara E., Abe K., and Nakazato Y. Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. Virchows Arch. 441 (2002) 358-367
79. Schneider J.S., Roeltgen D.P., Mancall E.L., Chapas-Crilly J., Rothblat D.S., and Tatarian G.T. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology 50 (1998) 1630-1636
80. Scorrano L., Petronilli V., Di Lisa F., and Bernardi P. Commitment to apoptosis by GD3 ganglioside depends on opening of the mitochondrial permeability transition pore. J. Biol. Chem. 274 (1999) 22581-22585
81. Silva R.H., Felicio L.F., Nasello A.G., Vital M.A., and Frussa-Filho R. Effect of ganglioside (GM1) on memory in senescent rats. Neurobiol. Ageing 17 (1996) 583-586
82. Silva R.H., Felicio L.F., and Frussa-Filho R. Ganglioside GM1 attenuates scopolamine-induced amnesia in rats and mice. Psychopharmacology (Berl.) 141 (1999) 111-117
83. Skaper S.D., Leon A., and Facci L. Death of cultured hippocampal pyramidal neurons induced by pathological activation of N-methyl-d-aspartate receptors is reduced by monosialogangliosides. J. Pharmacol. Exp. Ther. 259 (1991) 452-457
84. Svennerholm L., Brane G., Karlsson I., Lekman A., Ramstrom I., and Wikkelso C. Alzheimer disease-effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement. Geriatr. Cogn. Disord. 14 (2002) 128-136
85. Sweeney W.A., Luedtke J., McDonald M.P., and Overmier J.B. Intrahippocampal injections of exogenous beta-amyloid induce postdelay errors in an eight-arm radial maze. Neurobiol. Learn Mem. 68 (1997) 97-101
86. Tamboli I.Y., Prager K., Barth E., Heneka M., Sandhoff K., and Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280 (2005) 28110-28117
87. Tashima Y., Oe R., Lee S., Sugihara G., Chambers E.J., Takahashi M., and Yamada T. The effect of cholesterol and monosialoganglioside (GM1) on the release and aggregation of amyloid beta-peptide from liposomes prepared from brain membrane-like lipids. J. Biol. Chem. 279 (2004) 17587-17595
88. Wakabayashi M., Okada T., Kozutsumi Y., and Matsuzaki K. GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem. Biophys. Res. Commun. 328 (2005) 1019-1023
89. Walsh T.J., Emerich D.F., and Schmechel D.E. GM1 ganglioside attenuates the behavioral deficits but not the granule cell damage produced by intradentate colchicine. Brain Res. 478 (1989) 24-33
90. Williams M.A., and McCluer R.H. The use of Sep-Pak C18 cartridges during the isolation of gangliosides. J. Neurochem. 35 (1980) 266-269
91. Yanagisawa K., Odaka A., Suzuki N., and Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1 (1995) 1062-1066
92. Yu R.K., and Ledeen R.W. Gangliosides of human, bovine, and rabbit plasma. J. Lipid Res. 13 (1972) 680-686
93. Yuki N., Sato S., Miyatake T., Sugiyama K., Katagiri T., and Sasaki H. Motoneuron-disease-like disorder after ganglioside therapy. Lancet 337 (1991) 1109-1110
94. Zhu M.Y., Hasty A.H., Harris C., Linton M.F., Fazio S., and Swift L.L. Physiological relevance of apolipoprotein E recycling: studies in primary mouse hepatocytes. Metabolism 54 (2005) 1309-1315